| CAS: | 89268-62-2 | |
| 分子式: | C16H23N11O2S5 | |
| 分子量: | 561.75 | |
| 中文名称: |
| |
| 英文名称: |
|
| 货号 | 品牌 | 产品名称 | 规格 | 包装、参考价格 | |||||||||||||||||||||||||||||||||||||||
| D725290 | MACKLIN | 1,1'-(((((1,1-二氧代-2H-1,2,4,6-硫杂三嗪-3,5-二基)双(乙烷-2,1-二基))双(硫烷二基))二(亚甲基)双(噻唑-4,2-二基)二胍 | 97% | 680元/5mg; 1155元/10mg; 2310元/25mg; | 咨询 | ||||||||||||||||||||||||||||||||||||||
储存:-20°C, 避光, 惰性气体 | |||||||||||||||||||||||||||||||||||||||||||
| PHR2909 | Supelco | Famotidine Related Compound B | certified reference material, pharmaceutical secondary standard | 6680.32元/50 MG; | 咨询 | ||||||||||||||||||||||||||||||||||||||
产品说明 一般描述 Pharmaceutical secondary standards for application in quality control provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to the preparation of in-house working standards 分析说明 These secondary standards offer multi-traceability to the USP, EP and BP primary standards, where they are available. 其他说明 This Certified Reference Material (CRM) is produced and certified in accordance with ISO 17034 and ISO/IEC 17025. All information regarding the use of this CRM can be found on the certificate of analysis. 基本信息
产品性质
安全信息
| |||||||||||||||||||||||||||||||||||||||||||
| 1269221 | USP | Famotidine Related Compound B | United States Pharmacopeia (USP) Reference Standard | 11011.4元/25 MG; | 咨询 | ||||||||||||||||||||||||||||||||||||||
产品说明 一般描述 Famotidine Related Compound B (Famotidine Impurity B) is an impurity of famotidine, which is a hydrophilic, cationic, histamine H2 receptor antagonist drug that effectively inhibits gastric acid secretion in humans. 应用 Famotidine Related Compound B can be used as a pharmaceutical primary standard for the determination of the analyte in pharmaceutical formulations by various analytical techniques. 分析说明 These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind. 其他说明 Sales restrictions may apply. 基本信息
产品性质
安全信息
| |||||||||||||||||||||||||||||||||||||||||||